13. (Currently Amended) A <u>partial</u> peptide having affinity to gp120 represented by formula (2): Al'-Val-Lys-Ala-Gly-R (SEQ ID No. 2)

wherein, in the formula,

Al' is aspartic acid, lysine, valine, glutamic acid, glycine, asparagine, or a tyrosine residue; and

R is OH derived from a carboxyl group or NH₂ derived from an acid amide group.

14. (**Currently Amended**) A <u>partial</u> peptide having affinity to gp120 represented by formula (3): H-Asp-Val-Lys-Ala-A5'-R (SEQ ID No. 3)

wherein, in the formula,

H is hydrogen;

A5' is glycine, alanine, valine, leucine, isoleucine, serine, threonine, methionine, asparagine, glutamine, histidine, lysine, arginine, phenylalanine, tryptophan, proline, or a tyrosine residue; and R is OH derived from a carboxyl group or NH₂ derived from an acid amide group.

- 15. (**Currently Amended**) A <u>partial</u> peptide having affinity to gp120 <u>consisting of up to 10 amino</u> <u>acids</u> and comprising the amino acid sequence of Asp-Val-Lys-Ala-Gly (SEQ ID No. 1).
- 16. (Currently Amended) A The peptide according to claim 15 having affinity to gp120 represented by formula (4):

H-Gly-Asp-Val-Lys-Ala-Gly-R (SEQ ID No. 4),

wherein in the formula,

H is hydrogen; and

R is OH derived from a carboxyl group or NH₂ derived from an acid amide group.

17. (Currently Amended) A The peptide according to claim 15 having affinity to gp120 represented by formula (5):

H-Gly-Gly-Asp-Val-Lys-Ala-Gly-R (SEQ ID No. 5),

wherein in the formula,

H is hydrogen; and

R is OH derived from a carboxyl group or NH, derived from an acid amide group.

- 18. (**Currently Amended**) A compound, comprising the peptide as claimed in any one of claims 12 to 17, and bound to a macromolecule compound or a medicine medicinal compound.
- 19. (**Previously Presented**) The compound as claimed in claim 18, wherein said macromolecule compound comprises a synthetic polymer or a biopolymer.
- 20. (**Currently Amended**) The compound as claimed in claim 18, wherein the <u>medicine medicinal</u> compound is AZT.
- 21. (**Previously Presented**) A compound, comprising the peptide as claimed in any one of claims 12 to 17, or a pharmaceutically acceptable salt thereof.
- 22. (**Previously Presented**) The compound as claimed in claim 21, wherein the peptide is bound to a carrier.
- 23. (**Previously Presented**) A viral agglutination test compound, comprising the peptide as claimed in any one of claims 12 to 17.
- 24. (Previously Presented) A viral test kit, comprising the viral agglutination test compound of claim 23.
- 25. (Currently Amended) A method of removing HIV viruses comprising the steps of: contacting the compound as claimed in claim 22, with the HIV viruses; and absorbing and removing the HIV viruses which have affinity for the compound.